News
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary - As cancer rates climb ...
In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), Oncolytics's flagship pelareorep, an intravenously ...
With a focus on specialty shipments, including high-value electronics, IT equipment, artwork, and antiques, Craters & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback